Investigational Drug Cediranib Shows Promise In Patients With Recurrent Glioblastoma

Armen Hareyan's picture
Advertisement

Recurrent Glioblastoma

Advertisement

Data for the investigational agent cediranib were presented from a study in patients with recurrent glioblastoma, an invasive form of brain tumor with a high unmet medical need.

Cediranib Phase II monotherapy study in recurrent glioblastoma

Advertisement